Urine 5MedC, a Marker of DNA Methylation, in the Progression of Chronic Kidney Disease.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
01
2019
revised:
02
04
2019
accepted:
02
06
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
28
12
2019
Statut:
epublish
Résumé
Alterations in DNA methylation may be involved in disease progression in patients with chronic kidney disease (CKD). Recent studies have suggested that 5-methyl-2'-deoxycytidine (5MedC) may be a marker of hypermethylation of DNA. Currently, there is no information available regarding the urine levels of 5MedC and its association with the progression of CKD. We examined the urine levels of 5MedC in spot urine samples from 308 patients with CKD (median age: 56 years, male: 53.2%, and glomerulonephritis: 51.0%) using a competitive enzyme-linked immunosorbent assay and investigated the relationships among urine 5MedC, urine albumin, urine The urine 5MedC level was significantly increased in the later stages of CKD compared to the early to middle stages of CKD. In multiple logistic regression models, urine 5MedC was significantly associated with the prediction of later CKD stages. Urine 5MedC (median value, 65.9 The present data demonstrate that the urine 5MedC level is associated with a reduced renal function and can serve as a novel and potent biomarker for predicting the renal outcome in CKD patients. Further studies will be necessary to elucidate the role of urine DNA methylation in the progression of CKD.
Sections du résumé
BACKGROUND
BACKGROUND
Alterations in DNA methylation may be involved in disease progression in patients with chronic kidney disease (CKD). Recent studies have suggested that 5-methyl-2'-deoxycytidine (5MedC) may be a marker of hypermethylation of DNA. Currently, there is no information available regarding the urine levels of 5MedC and its association with the progression of CKD.
METHOD
METHODS
We examined the urine levels of 5MedC in spot urine samples from 308 patients with CKD (median age: 56 years, male: 53.2%, and glomerulonephritis: 51.0%) using a competitive enzyme-linked immunosorbent assay and investigated the relationships among urine 5MedC, urine albumin, urine
RESULTS
RESULTS
The urine 5MedC level was significantly increased in the later stages of CKD compared to the early to middle stages of CKD. In multiple logistic regression models, urine 5MedC was significantly associated with the prediction of later CKD stages. Urine 5MedC (median value, 65.9
CONCLUSION
CONCLUSIONS
The present data demonstrate that the urine 5MedC level is associated with a reduced renal function and can serve as a novel and potent biomarker for predicting the renal outcome in CKD patients. Further studies will be necessary to elucidate the role of urine DNA methylation in the progression of CKD.
Identifiants
pubmed: 31354889
doi: 10.1155/2019/5432453
pmc: PMC6636573
doi:
Substances chimiques
Biomarkers
0
Deoxycytidine Monophosphate
1032-65-1
deoxy-5-methylcytidylic acid
2498-41-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5432453Références
Nature. 1999 Feb 18;397(6720):579-83
pubmed: 10050851
J Pharm Biomed Anal. 1999 Dec;21(5):1045-51
pubmed: 10703973
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Curr Top Dev Biol. 2004;60:55-89
pubmed: 15094296
Nat Rev Genet. 2005 Aug;6(8):597-610
pubmed: 16136652
N Engl J Med. 2006 May 18;354(20):2122-30
pubmed: 16707749
Nature. 2007 Feb 8;445(7128):671-5
pubmed: 17268471
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
J Intern Med. 2007 May;261(5):488-99
pubmed: 17444888
Clin Biochem. 2007 Sep;40(13-14):936-8
pubmed: 17692303
Am J Nephrol. 2008;28(4):661-8
pubmed: 18337633
Trends Genet. 2009 Feb;25(2):82-90
pubmed: 19144439
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Science. 2009 May 15;324(5929):930-5
pubmed: 19372391
Science. 2009 May 15;324(5929):929-30
pubmed: 19372393
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 1;877(20-21):1957-61
pubmed: 19501556
Annu Rev Genet. 2009;43:143-66
pubmed: 19659441
Nat Med. 2010 May;16(5):544-50
pubmed: 20418885
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Oct 15;878(28):2765-9
pubmed: 20829131
Kidney Int. 2011 Jul;80(1):17-28
pubmed: 21150873
Cell Mol Life Sci. 2011 May;68(10):1681-702
pubmed: 21249513
Kidney Int. 2011 Jun;79(12):1331-40
pubmed: 21289598
Kidney Int. 2011 Oct;80(8):806-21
pubmed: 21697815
Lancet. 2012 Jan 14;379(9811):165-80
pubmed: 21840587
Anal Chim Acta. 2011 Oct 3;703(1):58-63
pubmed: 21843675
Perit Dial Int. 2012 Jul-Aug;32(4):453-61
pubmed: 22215657
Kidney Int. 2012 Apr;81(7):640-50
pubmed: 22237753
Chem Res Toxicol. 2012 Feb 20;25(2):462-70
pubmed: 22268645
Environ Health. 2012 May 02;11:31
pubmed: 22551203
Nephron Extra. 2012 Jan;2(1):159-68
pubmed: 22811689
Clin Exp Nephrol. 2013 Apr;17(2):155-73
pubmed: 23385776
PLoS One. 2013;8(2):e56695
pubmed: 23431388
Nephrol Dial Transplant. 2013 Jul;28(7):1663-71
pubmed: 23512108
Circ Heart Fail. 2013 Jul;6(4):662-8
pubmed: 23674363
Anal Bioanal Chem. 2013 Nov;405(27):8859-69
pubmed: 23978937
Hum Genet. 2014 Mar;133(3):281-97
pubmed: 24129831
Nat Med. 2013 Nov;19(11):1496-504
pubmed: 24141423
J Am Soc Nephrol. 2014 Jan;25(1):10-7
pubmed: 24179169
N Engl J Med. 2013 Dec 5;369(23):2183-96
pubmed: 24206458
Epigenetics. 2014 Mar;9(3):366-76
pubmed: 24253112
Nephrol Dial Transplant. 2014 Apr;29(4):864-72
pubmed: 24516231
J Clin Invest. 2014 Jun;124(6):2523-37
pubmed: 24812666
JAMA. 2014 Jun 25;311(24):2518-2531
pubmed: 24892770
Anal Chem. 2015 Feb 3;87(3):1846-52
pubmed: 25551771
Curr Drug Targets. 2015;16(1):13-9
pubmed: 25585126
J Am Soc Nephrol. 2015 Oct;26(10):2388-97
pubmed: 25653098
Aging Cell. 2015 Dec;14(6):924-32
pubmed: 25913071
JAMA. 2015 Sep 15;314(11):1129-30
pubmed: 26372577
Genome Med. 2016 Jan 19;8(1):5
pubmed: 26803900
Epigenetics. 2016 Apr 2;11(4):259-72
pubmed: 27018948
JAMA Psychiatry. 2016 May 1;73(5):506-14
pubmed: 27074206
Sci Rep. 2016 May 31;6:26969
pubmed: 27243754
Environ Int. 2016 Sep;94:583-590
pubmed: 27346742
Nature. 2016 Sep 1;537(7618):63-68
pubmed: 27533040
Epigenetics. 2017 Jun 3;12(6):401-415
pubmed: 28059593
PLoS Med. 2017 Jan 17;14(1):e1002215
pubmed: 28095459
J Hazard Mater. 2017 Jun 5;331:329-335
pubmed: 28273583
PLoS One. 2017 Mar 29;12(3):e0174551
pubmed: 28355260
Nutr Metab Cardiovasc Dis. 2017 Sep;27(9):822-829
pubmed: 28755807
Ren Fail. 2017 Nov;39(1):597-601
pubmed: 28805547
Diabetes Res Clin Pract. 2017 Oct;132:127-136
pubmed: 28834773
Clin Exp Nephrol. 2018 Apr;22(2):318-327
pubmed: 28884361
Biomed Res Int. 2018 Apr 3;2018:3024698
pubmed: 29850501
Nephrology (Carlton). 2018 Sep;23(9):855-862
pubmed: 29987860
Nat Med. 2018 Nov;24(11):1721-1731
pubmed: 30275566
PLoS One. 2018 Nov 6;13(11):e0205791
pubmed: 30399190
Ther Drug Monit. 2019 Apr;41(2):213-226
pubmed: 30883514
Clin Chim Acta. 1995 Jan 31;234(1-2):37-45
pubmed: 7758221
Nucleic Acids Res. 1993 Nov 25;21(23):5323-7
pubmed: 8265344